Actively Recruiting

Age: 15Years +
All Genders
NCT07136116

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

Led by AbbVie · Updated on 2026-04-13

200

Participants Needed

28

Research Sites

225 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice. Risankizumab is an approved drug for treating participants with ulcerative colitis. Approximately 200 participants who are prescribed risankizumab by their physician in accordance with local label will be enrolled in approximately 30 sites across Japan. Participants will receive risankizumab as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 156 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

CONDITIONS

Official Title

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

Who Can Participate

Age: 15Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of moderate to severe Ulcerative Colitis
  • Started risankizumab treatment prescribed as routine care under Japan approved label
  • Prescription decision made before and independently of study participation
  • Able to provide voluntary informed consent (or parent/legal guardian consent if under 18)
  • Able to understand, communicate, and comply with study requirements including use of a smart device for data collection
  • No prior exposure to risankizumab
  • Not currently participating in interventional research (excluding non-interventional studies, PMOS, or registries)
Not Eligible

You will not qualify if you...

  • See Inclusion Criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 28 locations

1

Aichi Medical University Hospital /ID# 278155

Nagakute, Aichi-ken, Japan, 480-1195

Actively Recruiting

2

Nagoya University Hospital /ID# 278159

Nagoya, Aichi-ken, Japan, 466-8560

Actively Recruiting

3

Hirosaki University Hospital /ID# 278153

Hirosaki, Aomori, Japan, 036-8563

Actively Recruiting

4

Chiba University Hospital /ID# 277669

Chiba, Chiba, Japan, 260-8677

Actively Recruiting

5

Tsujinaka Hospital - Kashiwanoha /ID# 277672

Kashiwa-shi, Chiba, Japan, 277-0871

Actively Recruiting

6

Toho University Sakura Medical Center /ID# 277536

Sakura, Chiba, Japan, 285-0841

Actively Recruiting

7

Kyushu University Hospital /ID# 278077

Fukuoka, Fukuoka, Japan, 812-8582

Actively Recruiting

8

Sapporo Medical University Hospital /ID# 277535

Sapporo, Hokkaido, Japan, 060-8543

Actively Recruiting

9

Hokkaido University Hospital /ID# 277668

Sapporo, Hokkaido, Japan, 060-8648

Actively Recruiting

10

Sapporo Higashi Tokushukai Hospital /ID# 278123

Sapporo, Hokkaido, Japan, 065-0033

Actively Recruiting

11

Kobe University Hospital /ID# 278292

Kobe, Hyōgo, Japan, 650-0017

Actively Recruiting

12

Hyogo Medical University Hospital /ID# 277676

Nishinomiya-shi, Hyōgo, Japan, 663-8501

Actively Recruiting

13

University Hospital Kyoto Prefectural University of Medicine /ID# 277541

Kyoto, Kyoto, Japan, 602-8566

Actively Recruiting

14

Kansai Medical University Hospital /ID# 278619

Hirakata-shi, Osaka, Japan, 573-1191

Actively Recruiting

15

Saga University Hospital /ID# 278160

Saga, Saga-ken, Japan, 849-8501

Actively Recruiting

16

Saitama Medical Center /ID# 278076

Kawagoe, Saitama, Japan, 350-8550

Actively Recruiting

17

Shiga University of Medical Science Hospital /ID# 277540

Ōtsu, Shiga, Japan, 520-2192

Actively Recruiting

18

Hamamatsu University Hospital /ID# 277539

Hamamatsu, Shizuoka, Japan, 431-3192

Actively Recruiting

19

NHO Shizuoka Medical Center /ID# 278075

Sunto-gun, Shizuoka, Japan, 411-8611

Actively Recruiting

20

Dokkyo Medical University Hospital /ID# 278152

Mibu, Tochigi, Japan, 321-0293

Actively Recruiting

21

Institute of Science Tokyo Hospital /ID# 277538

Bunkyo-ku, Tokyo, Japan, 113-8519

Actively Recruiting

22

Kitasato University Kitasato Institute Hospital /ID# 278154

Minato-ku, Tokyo, Japan, 108-8642

Actively Recruiting

23

Kyorin University Hospital /ID# 277534

Mitaka-shi, Tokyo, Japan, 181-8611

Actively Recruiting

24

Fukuoka University Hospital /ID# 277677

Fukuoka, Japan, 814-0180

Actively Recruiting

25

Hiroshima University Hospital /ID# 277542

Hiroshima, Japan, 734-8551

Not Yet Recruiting

26

Sapporo Kosei General Hospital /ID# 278048

Sapporo, Japan, 060-0033

Actively Recruiting

27

The Jikei University Hospital /ID# 278122

Tokyo, Japan, 105-8461

Actively Recruiting

28

Toyama University Hospital /ID# 277675

Toyama, Japan, 930-0194

Actively Recruiting

Loading map...

Research Team

A

AbbVie GK Clinical Trial Registration Desk

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis | DecenTrialz